FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014169246> ?p ?o ?g. }

• W2014169246 abstract "Purpose of the study Few clinical trials have compared non-nucleoside reverse transcriptase inhibitors (NNRTI) and ritonavir-boosted protease inhibitors (PI/r) as initial combined antiretroviral therapy (cART) for HIV-1-infected patients with high plasma viral load (pVL), and non-conclusive results have been reported. We compared the effectiveness between NNRTI and PI/r as first-line cART for HIV-1-infected patients with high pVL. Methods Observational retrospective study of 664 consecutive treatment-naïve HIV-1-infected patients with pVL (HIV-1 RNA) >100,000 copies/mL who initiated NNRTI or PI/r-based cART between 2000–2010 in three University hospitals. Only currently preferred or alternative regimens in clinical guidelines were included. Primary endpoint: percentage of therapeutic failures at week 48. Virologic failure was defined as: a) lack of virologic response (<1 log RNA HIV-1 decrease in first 3 months); b) RNA HIV-1 >50 c/mL at week 48; c) confirmed rebound >50 c/ml after a previous value <50 c/mL. Intent-to-treat (ITT noncompleter=failure) and on-treatment (OT) analyses were performed. Results 62% of patients initiated NNRTI-regimens (83% efavirenz) and 38% PI/r-regimens (62% lopinavir/). Baseline characteristics: male 83%; median age 39 yrs; median CD4 count: 212/µL (NNRTI 232 vs PI/r 177, p=0.028); pVL 5.83 log10 c/mL (NNRTI 5.43 vs PI/r 5.55, p=0.007); AIDS 24% (NNRTI 21% vs PI/r 29%, p=0.015). NRTI backbones were tenofovir plus 3TC or FTC in 72%. The percentage of therapeutic failure was higher in the PI/r group (ITT NC=F 26% vs 18%, p=0.012) with no differences in virologic failures (PI/r 5%, NNRTI 6%, p=0.688). The rate of treatment changes due to toxicity and/or voluntary discontinuations was higher in the PI/r group (15% vs 8%, p=0.008). A multivariate analysis adjusted for age, gender, CD4 count, VL and AIDS showed NNRTI vs PI/r as the only variable associated with treatment response (OR 0.61, 95% CI 0.41–0.88). Median pVL and rate of resistance at virologic failure were higher in patients receiving NNRTI (3.97 vs 2.49 log copies/mL, p<0.001 and 62% vs 12%, p=0.004, respectively). Conclusions Initial NNRTI-regimens showed higher effectiveness compared with PI/r-regimens in HIV-1-infected patients with high pVL, although virologic failure rates were low and comparable. Resistance emergence was more frequent and pVL higher in patients failing NNRTI. However, more patients initiating PI/r-based regimens changed or discontinued therapy." @default.
• W2014169246 created "2016-06-24" @default.
• W2014169246 creator A5009094454 @default.
• W2014169246 creator A5012384912 @default.
• W2014169246 creator A5020210842 @default.
• W2014169246 creator A5022774332 @default.
• W2014169246 creator A5028685841 @default.
• W2014169246 creator A5043509211 @default.
• W2014169246 creator A5053140952 @default.
• W2014169246 creator A5059398898 @default.
• W2014169246 creator A5063841440 @default.
• W2014169246 creator A5082954957 @default.
• W2014169246 creator A5083797493 @default.
• W2014169246 date "2012-11-11" @default.
• W2014169246 modified "2023-10-17" @default.
• W2014169246 title "Effectiveness of first-line antiretroviral therapy based on NNRTIs vs ritonavir-boosted PIs in HIV-1 infected patients with high plasma viral load" @default.
• W2014169246 doi "https://doi.org/10.7448/ias.15.6.18235" @default.
• W2014169246 hasPublicationYear "2012" @default.
• W2014169246 type Work @default.
• W2014169246 sameAs 2014169246 @default.
• W2014169246 citedByCount "0" @default.
• W2014169246 crossrefType "journal-article" @default.
• W2014169246 hasAuthorship W2014169246A5009094454 @default.
• W2014169246 hasAuthorship W2014169246A5012384912 @default.
• W2014169246 hasAuthorship W2014169246A5020210842 @default.
• W2014169246 hasAuthorship W2014169246A5022774332 @default.
• W2014169246 hasAuthorship W2014169246A5028685841 @default.
• W2014169246 hasAuthorship W2014169246A5043509211 @default.
• W2014169246 hasAuthorship W2014169246A5053140952 @default.
• W2014169246 hasAuthorship W2014169246A5059398898 @default.
• W2014169246 hasAuthorship W2014169246A5063841440 @default.
• W2014169246 hasAuthorship W2014169246A5082954957 @default.
• W2014169246 hasAuthorship W2014169246A5083797493 @default.
• W2014169246 hasBestOaLocation W20141692461 @default.
• W2014169246 hasConcept C126322002 @default.
• W2014169246 hasConcept C127413603 @default.
• W2014169246 hasConcept C142462285 @default.
• W2014169246 hasConcept C159047783 @default.
• W2014169246 hasConcept C203092338 @default.
• W2014169246 hasConcept C2777182164 @default.
• W2014169246 hasConcept C2777275308 @default.
• W2014169246 hasConcept C2777351918 @default.
• W2014169246 hasConcept C2779298103 @default.
• W2014169246 hasConcept C2781143361 @default.
• W2014169246 hasConcept C2781432083 @default.
• W2014169246 hasConcept C2993143319 @default.
• W2014169246 hasConcept C3013748606 @default.
• W2014169246 hasConcept C535046627 @default.
• W2014169246 hasConcept C71924100 @default.
• W2014169246 hasConcept C78519656 @default.
• W2014169246 hasConcept C90924648 @default.
• W2014169246 hasConceptScore W2014169246C126322002 @default.
• W2014169246 hasConceptScore W2014169246C127413603 @default.
• W2014169246 hasConceptScore W2014169246C142462285 @default.
• W2014169246 hasConceptScore W2014169246C159047783 @default.
• W2014169246 hasConceptScore W2014169246C203092338 @default.
• W2014169246 hasConceptScore W2014169246C2777182164 @default.
• W2014169246 hasConceptScore W2014169246C2777275308 @default.
• W2014169246 hasConceptScore W2014169246C2777351918 @default.
• W2014169246 hasConceptScore W2014169246C2779298103 @default.
• W2014169246 hasConceptScore W2014169246C2781143361 @default.
• W2014169246 hasConceptScore W2014169246C2781432083 @default.
• W2014169246 hasConceptScore W2014169246C2993143319 @default.
• W2014169246 hasConceptScore W2014169246C3013748606 @default.
• W2014169246 hasConceptScore W2014169246C535046627 @default.
• W2014169246 hasConceptScore W2014169246C71924100 @default.
• W2014169246 hasConceptScore W2014169246C78519656 @default.
• W2014169246 hasConceptScore W2014169246C90924648 @default.
• W2014169246 hasIssue "6(Suppl 4)" @default.
• W2014169246 hasLocation W20141692461 @default.
• W2014169246 hasLocation W20141692462 @default.
• W2014169246 hasOpenAccess W2014169246 @default.
• W2014169246 hasPrimaryLocation W20141692461 @default.
• W2014169246 hasRelatedWork W1965602853 @default.
• W2014169246 hasRelatedWork W1988732321 @default.
• W2014169246 hasRelatedWork W2014169246 @default.
• W2014169246 hasRelatedWork W2132291963 @default.
• W2014169246 hasRelatedWork W2135598577 @default.
• W2014169246 hasRelatedWork W2171775419 @default.
• W2014169246 hasRelatedWork W2263963452 @default.
• W2014169246 hasRelatedWork W2412211511 @default.
• W2014169246 hasRelatedWork W2503404095 @default.
• W2014169246 hasRelatedWork W3150501237 @default.
• W2014169246 hasVolume "15" @default.
• W2014169246 isParatext "false" @default.
• W2014169246 isRetracted "false" @default.
• W2014169246 magId "2014169246" @default.
• W2014169246 workType "article" @default.